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Solid state synthesis of high-quality indomethacin-saccharin cocrystals was achieved using Hot 
Melt Extrusion. The physical and chemical stability of the formed cocrystals was enhanced 
through co – processing with inert excipients at the final kneading zone. For the purposes of the 
study the synthesized cocrystals were co-processed with a crystalline hydrophilic polymer (PEG 
6000), an amorphous hydrophilic polymer (hydroxypropylmethyl cellulose, HPMC) and an 
aluminometacilicate inorganic (Neusilin) excipient. Physiochemical characterization of the 
suspended cocrystals in the Neusilin and HPMC carriers revealed superior stability and the absence 
of any interactions between the excipients and the parent cocrystals. In contrast extruded cocrystals 
that were not suspended in any excipient or co-processed with PEG 6000 underwent disassociation 
under accelerated conditions. Surface dissolution analysis demonstrated that Neusilin and 
PEG6000 have no effect on the cocrystal dissolution rates (>90%) while HPMC led to in – situ 
gelling effect and hence in slower rates ( 4%) In conclusion, cocrystals with high crystallinity 
and improved physicochemical stability can be synthesised by co-processing with excipients that 
are inert, non- miscible, have good thermal stability and a low viscosity.  
 








A cocrystal is a multicomponent molecular crystal in which all components are at a 
stoichiometric ratio and comprise of two or more chemically different molecules. 1,2 Cocrystal 
synthesis involves the formation of supramolecular heterosynthons of certain functional groups 
which are non-covalently bonded. These molecular interactions result in either H – bonding or the 
formation of van der Waals forces which make up the structure of thermodynamically stable 
cocrystals. 3 Cocrystallization offers an expedient way to alter the physicochemical properties of 
APIs including dissolution rate, intrinsic solubility, melting point, hygroscopicity, compressibility, 
bulk density and friability. 4 There has been a recent surge in industrial interest into cocrystals due 
in part to their potential to improve the physicochemical properties of poorly bioavailable API; 
advances in continuous manufacturing technologies, leading to fewer production steps and 
increased cost effectiveness; improving regulatory and intellectual property factors, potential for 
green synthesis and the innate advantages to working with known API as opposed to new drugs. 
5-7 
Pharmaceutical cocrystals tend to exhibit specific physical stability issues. One of the biggest 
examples of these issues is that caused by hydrate formation. Due to their small size and multi-
directional hydrogen bonding abilities, it is common for the API of a cocrystal to form a hydrate 
with water molecules. This is particularly common at higher temperatures and humidities due to 
moisture uptake from the atmosphere, potentially converting the drug into its hydrated form. 
Reversible hydrate formation indicates that neither the anhydrate nor the hydrate is physically 
stable across the range of common processing conditions. 8 This can be observed in the case of 
Theophylline/citric acid cocrystals where the cocrystal was observed to convert to the cocrystal 
hydrate after 3 days at 75% relative humidity (RH). 9   
 5 
It has been shown that coformers which modulate both solubility and water activity, such as 
citric acid or saccharin, are predisposed to conversions due to the moisture uptake at high 
humidities and the coformers deliquescence causing dissolution into the absorbed water. 10-12 The 
removal and/or alteration of the coformer will result in the disassociation of the parent API crystals, 
formation of API hydrate crystals or other cocrystal forms which can potentially lower the 
solubility and reduce the bioavailability of the drug. 13 Other studies have noted the occurrence of 
cocrystal dissociation due to partial dissolution of one of the parent compounds at elevated 
temperatures and humidities. Eddleston et al. (2014) reported that Theophylline and Caffeine 
cocrystals with dicarboxylic acid coformers experienced partial dissociation at 75%, 85% and 95% 
RH, due to partial dissolution of the coformers. 14 The cocrystals dissociated due to aqueous 
solubility differences between the API and coformers, causing coformer dissolution and 
recrystallization of the bulk API. This has been noted in API-coformer pairs whose relative 
solubilities differ by as little as 30%. 15 
An emerging approach designed to increase the chemical and physical stability of cocrystals 
involves co-processing the API-coformer pairs alongside inert excipients. This approach, dubbed 
matrix-assisted cocrystallization (MAC) in one study, sees the API-coformer pair blended with an 
inert third material prior to or during a hot-melt extrusion (HME) process. 16-19 Using the typical 
MAC approach, all constituents are pre-mixed and fed into the extruder together. Cocrystallization 
occurs across the extruder barrel, facilitated by intimate grinding at temperatures near the melting 
or softening point of the added excipient. This causes the cocrystals to become imbedded in a 
protective matrix once the excipients solidify.  
This approach was first conceived by Liu et al. (2011), who co-extruded 
carbamazepine/nicotinamide cocrystals with HPMC, Soluplus® (PVAc-PVCap- PEG) or PVP/VA 
 6 
polymer excipients (60:40 amounts). 16 Here, cocrystals formed in-situ before melting at 160 °C 
and becoming completely dispersed in the polymer carrier forming an amorphous solid dispersion. 
However, X-ray analysis revealed that prior to melting the cocrystals were embedded in the 
polymer matrices. This was expanded upon by Boksa et al. (2014) who employed a similar MAC 
method, but this time at lower temperatures with the intent to form cocrystals as opposed to solid 
dispersions. 17 Here, carbamazepine-nicotinamide cocrystals co-processed with Soluplus® were 
found to produce cocrystals embedded in a polymer matrix. Partial least square regression models 
and X-ray powder diffraction (XRPD) revealed the extruded cocrystals found only 0.3% (±2.9) of 
unconverted CBZ and NIC in the extruded samples. 17 
A recent study Li et al. (2016) helped shed some light on the quality’s excipient must possess to 
allow the formation high quality cocrystals. 18 The added excipient must be completely inert and 
not miscible with the API- coformer pair, have a sufficiently lower processing temperature than 
the cocrystal constituents, have a low melting viscosity and must solidify quickly upon cooling. 
Thus, the added excipient is inert is of utmost importance, as any strong non-covalent interaction 
between constituents other than between the API-coformer pair has the potential to negatively 
affect cocrystal yield. XRPD analysis of MAC extruded Ibuprofen (IBU) – Isonicotinamide 
(IsoNA) cocrystals processed alongside either EPO or Soluplus®, showed absence of characteristic 
peaks associated with the IBU-IsoNA cocrystal, indicating a reduction in yield. This is likely 
because the highly miscible polymers interacted with the IBU, hindering interaction with the 
coformer. The highly viscous Soluplus would have prevented interaction between the API and 
coformer in its liquid state. This is also true for the EPO and is exacerbated by the polymers 
tendency to form hydrogen bonds with carboxylic acids, causing competition for the IsoNA 
coformer, hindering cocrystallization.  
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Conversely, extrusion of IBU-IsoNA cocrystals was possible when processed alongside Xylitol. 
This can be attributed to the tendency for polyols to be inert during extrusion, and xylitol’s low 
viscosity combined with is decreased miscibility allowing for increased molecular mobility and 
the rapid solidification. 17-20 However, a remaining barrier to the success of this method was the 
presence of amorphous IBU existing within the inert xylitol matrix, a trend which has been 
observed in previous studies. 16-18 A possible explanation for this is that the addition of any matrix, 
in high concentrations will hinder the interactions of the API-coformer pair at a molecular level. 
This is due to the increased interactions made possible due to the high-shear kneading zones of the 
extruder causing dispersive mixing and thus encouraging interaction between the excipient and 
drug-coformer pair. 21 It is possible that if the excipients were added in low concentrations at a 
later stage in the extrusion process, avoiding the kneading zones, that the excipient will act merely 
as a protective matrix and not interact with the cocrystals. 
In this study, indomethacin-saccharin cocrystals were co-processed with three different inert 
excipients, which will be fed separately into the extruders conveying zones after the final extruder 
kneading zone. The three excipients chosen for this work are Neusilin (NEU), hydroxypropyl 
methylcellulose (HPMC) and Polyethylene glycol (PEG) 6000. NEU, a synthetic amorphous form 
of magnesium aluminometasilicate, is an inert absorbent excipient with thermally stability up to 
700 °C and has been known to help stabilize moisture sensitive APIs. 22,23 HPMC is an inert, 
amorphous, hydrophilic, polysaccharide with good thermal stability. PEG 6000 is a crystalline, 
hydrophilic polymer, which is water soluble. Due to the relatively low melting point (60-64C) of 
PEG 6000, the extrusion process will operate well above the melting point of this particular 
excipient. The reason for this is to observe how the excipient will affect the quality of the cocrystal 
when completely melted, but still beyond the kneading zones. To examine the effect of excipient 
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concentration/loading on crystallinity, two batches for each excipient were processed, one with a 
5% excipient loading and another with 10% excipient loading.  
It is anticipated that by feeding the excipients into the extruder at a later stage, there will be 
insufficient mechanical energy and dispersive mixing to allow significant molecular interactions 
between the cocrystal and the excipient, while still allowing the formation of a protective matrix 
around the cocrystals. This protective matrix should enhance the long-term stability of the 
cocrystals and preserve crystallinity.  
 
Materials and methods 
Materials 
Indomethacin (γ-form, IND, >98.0%) was purchased from Tokyo Chemical Industry Co., Ltd 
(Tokyo, Japan). Both Saccharin (SAC, >99%) and Polyethylene glycol 6000 (PEG 6000) were 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK). Neusilin US2 (NEU, >99%) and 
hydroxypropyl methyl cellulose grade PHARMACOAT 603 (3 cP) were by kindly donated by 
Fuji Chemical Industries Co., Ltd. (Kamiichi, Toyama, Japan) and ShinEtsu (Tokyo, Japan) 
respectively, and were used as received. All solvent used for HPLC analysis were of analytical 
grade (Fisher Chemical, Loughborough, UK). 
 
Hot-melt extrusion Processing 
A 100g physical mixture of IND and SAC (1:1 stoichiometric ratio) was prepared by accurately 
weighting and then homogeneously blending in a Turbula TF2 mixer (Willy A. Bachofen AG, 
Switzerland) at 100rpm for 10 minutes. The blend was then placed inside a single-screw 
volumetric feeder (Brabender Technology, Duisburg, Germany), where the feed rate was 
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calibrated before being fed into a 16mm twin screw extruder (Eurolab 16, Thermo Fisher, 
Germany).  A second single screw gravimetric feeder of our own construction was placed above 
an entry port just after the final kneading zone, to feed excipients onto desired batches mid-process. 
This was not present for the unmodified cocrystal batches. This feeder was loaded with either 
NEU, HPMC or PEG 6000 in amounts equivalent to 5% or 10% of the cocrystal mixture amount. 
Travel time was calculated from the moment the blended mixture was first fed into the extruder to 
the moment it reached the second feeder. The time for the entire batch to pass this point was also 
taken. This was necessary to ensure the added excipient was equally dispersed throughout the 
entire cocrystal batch. The feed rate of the second feeder was calibrated in preliminary experiments 
to allow the amount of excipient to be evenly distributed throughout the cocrystal batch. This 
experiment was conducted without a die. Complete temperature profile is as follows: 50 °C, 70 
°C, 95 °C, 155 °C, 165 °C, 165 °C, 165 °C, 165 °C, 165 °C.  
 
Differential scanning Calorimetry (DSC)  
The thermal profiles for the Bulk IND and SAC, a physical mixture of the two, unmodified 
IND/SAC cocrystals and the excipient blended IND/SAC cocrystals were examined using a 
differential scanning calorimeter (Mettler Toledo 823e, Greifensee, Switzerland). The unmodified 
cocrystals and excipient blended cocrystals were further analysed after 4 weeks storage under 
accelerated conditions to check for changes in crystallinity. Each pan was analysed from 25-250 
°C (with the exception of the bulk IND, which was heated from 25-250 °C) at a heating rate of 10 
°C/min. Nitrogen was utilized as the purge gas and was supplied at 50 mL/min. STARe excellence 
Software was used for the data integration and evaluation.  
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X-ray Powder Diffraction (XRPD) 
The crystallinity of bulk components, physical mixtures, unmodified cocrystals and excipient 
blended IND/SAC cocrystals were determined using a Bruker D8 Advance X-ray diffractometer 
(Karlsruhe, Germany) in theta-theta mode. A Cu anode powered at 40 kV and 40 mA, a primary 
4°Soller slit and a secondary 2.5° Soller slit, and a 0.2mm exit slit was selected for this experiment. 
A LynxEye Position Sensitive detector with 3° opening, set at 6.5mm was utilized and a primary 
Göbel mirror was used for the parallel beam and the removal of CuKβ. Sample rotation was set at 
15rpm and data was collected between 2-55° 2θ with a step size set at 0.02° 2θ and the counting 
time set at 0.3 secs per step. EVA phase analysis software (Bruker, Germany) was used to identify 
peak positions and intensities of the bulk and extruded samples. Rietveld refinements were 
conducted using TOPAS V4.2 (Bruker, Germany), to validate the crystallinity of the pure and 
excipient blended IND/SAC cocrystal samples and compare to documented references taken from 
the Cambridge structural database (CSD). 24 XRPD analysis and Rietveld refinements were again 
conducted on all samples after stability studies to observe changes after being held under 
accelerated conditions. CSD crystal structures retrieved and used for Rietveld refinements; IND 
(γ-form) IND Refcode: INDMET02, 25 SAC Refcode: SCCHRN02, 26 and IND/SAC cocrystal 
Refcode: UFERED 27. 
 
Scanning electron microscopy (SEM) 
The morphology of the bulk components, physical mixtures, unmodified and excipient blended 
IND/SAC cocrystals was observed via scanning electron microscope (EVO MA10, Ziess, 
Germany). Samples were placed on a thin aluminium stub glazed with Mikrostik nonconductive 
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adhesive (Agar scientific, UK) and chromium coated under an argon atmosphere. The accelerating 
voltage of the electron beam was 11 kV. 
 
Particle size analysis 
Laser diffraction was used to measure the particle size distribution of the bulk components, 
unmodified and excipient blended IND/SAC cocrystals. This was achieved using a dry powder 
dispersion unit (Scirocco 2000) of a Mastersizer 2000 laser diffraction particle size analyser 
(Malvern, Worcestershire, UK). 5g of powder from each sample was placed in a vibratory tray 
which in turn fed the powder into the sample dispersion unit. Sampling time was set at 15 seconds 
and each sample was measured in triplicate.  
 
In vitro dissolution study 
Dissolution studies were carried out using a USP II apparatus (Varian 705 DS, North Carolina, 
US). Amounts of bulk IND, unmodified IND/SAC cocrystal and all excipient blended IND/SAC 
cocrystals equivalent to 25mg of IND were placed in a dissolution vessel filled with 900mL of 
phosphate buffer solution (pH 6.8). The temperature of the medium was maintained at 37 °C and 
paddle rotation was set at 100rpm. Samples were extracted via syringe in amounts of 2mL at 15, 
30, 60 and 120 min intervals, before being passed through 200μm filter.  
 
HPLC analysis 
Analysis was carried out using a HPLC system (Agilent technologies, 1200 series, 
Massachusetts, USA) equipped with a quaternary pump. The mobile phase consisted of 
methanol/water/acetic acid with a 70/30/0.2 ratio (v/v/v). A Hichrom S50DS2-4889 (5μm × 
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150mm × 4mm) column was used, with the temperature set at 25 °C. The injection volume was 
set at 20μm and the flow rate was maintained at 1.5mL/min with a 4 minute retention time. The 
eluent was monitored with a UV detector set at a wavelength of 260nm. The calibration curve for 
IND was prepared with a concentration range of 10−50μg/mL. 
 
Surface dissolution imaging (SDI) 
The dissolution behaviour and intrinsic dissolution rate (IDR) for the unmodified and all 
excipient blended IND/SAC cocrystals were studied using a Sirius SDI 300 (Forest Row, UK) 
fitted with ActiPix UV area imaging technology. The dissolution imaging experiments were 
performed at 37 °C at a single wavelength filter of 280nm. The dissolution occurred in 200mM of 
phosphate buffer (pH 6.5) at a flow rate of 0.2mL/min. Each sample was analysed for 20 minutes 
in triplicate. Compacts were compressed at a constant pressure (40 cN.m), for 1 min using a 
Quickset minor torque wrench (Torqueleader, M.H.H. engineering Co. Ltd., Guildford, UK). 
Calibration was performed through UV imaging a set of varying concentration IND standard 
solutions in distilled water. The calibration curve was constructed by plotting absorbance against 
the concentration of each standard solution. IDR values were determined using calculated 
extinction coefficients for each of the compounds.  
 
Stability studies 
The unmodified IND/SAC cocrystals and excipient blended cocrystals were placed in a sealed 
desiccator and kept under accelerated conditions of 40 ± 1 ºC and 75 ± 1.5% RH as per ICH 
guidelines, for a period of 4 weeks to ascertain the stability of the cocrystals at accelerated 
conditions. 28 To ensure the experimental conditions remained within the recommended limits, the 
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desiccator was kept in a temperature-controlled oven with the humidity verified daily using a 
hygrometer.  
 
Results and Discussion 
Structural analysis 
Indomethacin-Saccharin cocrystals were chosen as the model drug for this work due to the 
extensive amount of coverage this particular cocrystal pair has received, leaving little chance for 
unexplained occurrences. A quick screening using Mercury CSD 3.9 revealed that IND-SAC 
cocrystal contains a robust interaction between the carboxylic acid homodimer synthon found in 
the IND and the strong N-H donor group found in the SAC component (Figure 1). 26 In addition 
to this, the formation of a second imide dimer synthon has been reported, due to the lack of steric 
effects in relation to the carboxylic acid dimer. These carboxylic acid groups have been reported 
to form vigorous supramolecular synthons throughout the cocrystal lattice, resulting in greater 
thermostability than indomethacin cocrystals prepared with, for example, a coformer containing 
an amide group such as nicotinamide. 27 Further the screening revealed the cocrystal to have high 
H-bond propensities and easily accessible crystal geometries resulting in a strong and stable 




Figure 1: molecular models of A: Two molecules of Indomethacin (γ-form), forming a robust 
carboxylic acid dimer synthon. B: Single Molecule of Saccharin. C: Indomethacin-Saccharin 
Cocrystal interconnected via a Carboxylic acid homodimer synthon and Imide dimer synthons with 
N–H⋯O bonds.  
Hot Melt Extrusion Continuous Processing 
To accommodate the addition of the second feeder, the screw configuration had to be rearranged 
to ensure the excipients were fed into the device after the final kneading zone. The final kneading 
zone was shortened to allow for this, with three conveying elements being removed and the 
kneading elements pushed further down the screw in their place. The bulk cocrystal constituents 
were fed into the extruder at the beginning of the screw barrel through the first entry point. The 
excipients were fed into the barrel through a second feeder set up after the third kneading zone, 
through the final entry point, before the discharge zone. In total, the kneading elements were 
assembled in three separate “mixing zones” with 4 separate conveying zones, including one 
extended conveying zone towards the end of the extruder starting at the entry point for the second 
feeder, where the excipients were added (Images available in supporting information Figure S1, 
S2 and S3). Screw configuration was arranged with kneading zone components set at 90° angles 
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to allow for more aggressive, disruptive mixing. 29 DSC analysis indicates that this alteration 
allowed complete cocrystallization to occur by the 4th entry point, so excipients were added after 
the cocrystals had fully formed. Screw speed, temperature profile and feed rate were then adjusted 
to find the optimal processing parameters. (Table of trials available in supporting information 
Figure S4).  Dhumal et al. (2010) presented the importance of processing parameters such as screw 
speed, barrel temperature profile and screw configuration on the yield and purity of extruded 
cocrystals, emphasizing the effect the screw configuration has in creating enough energy to 
encourage cocrystallization. 30 By calibrating the excipients feed rate to correlate with the cocrystal 
feed rate it was possible to ensure all excipients were evenly distributed along the entire cocrystal 
batch. 
The high screw temperature should prove sufficient energy to liquefy/soften the excipient while 
the screw rotation should allow it to intersperse around the already co-crystallized API-coformer 
pair. However, as the mixture will not pass through a kneading zone, there will be insufficient 
mechanical energy and dispersive mixing to allow significant molecular interactions between the 
cocrystal and the excipient. As the excipient is not interspersed throughout the crystal lattice it 
should instead act merely as a protective matrix for the cocrystal. It is hoped that this matrix will 
hinder moisture uptake and discourage hydrogen bonding at high temperatures and humidities.  
This will prevent the solubilisation of the coformer due to aqueous solubility differences, leading 
to cocrystal disassociation and protect against hydrate formation. 14, 31, 32 
 
Thermal analysis 
The thermal properties of the bulk powders, physical mixture and unmodified IND/SAC can be 
seen in the supporting information (Figure S5). The bulk IND displayed a sharp melting peak at 
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160.9 °C, with the SAC showing a sharp melting point at 226.9 °C, in accordance with reported 
thermal behaviour. 27 For the physical mixture, an endothermic peak can be observed at 157.1 °C, 
immediately followed by an exothermic event at 159.2 °C. The endothermic peak can be attributed 
to a eutectic melting of the components, with the small exothermic event indicating the point in 
which cocrystallization has taken place. 33 This shows that cocrystallization is likely between the 
two components and also reveals that spontaneous cocrystal formation had not taken place during 
the preparation of the physical blend. Had cocrystallization already occurred a single cocrystal 
melt would be shown as opposed to the cocrystal forming point observed at Tmax 159.2 °C. 
34
 A 
more intense, narrow endothermic peak can be seen at 183.2 °C, which according to Basavoju et 
al. (2008) is in accordance with the melting point of the IND/SAC cocrystal. 27 The thermal profile 
of the unmodified IND/SAC cocrystal displays a single endotherm for the melting point of the 
cocrystal with an absence of any eutectic event or unbound/absorbed solvent or water present.  
This demonstrates the stability of the phase until the melting indicating complete batch 
cocrystallization and a high cocrystal purity. 35 
The thermogram for the excipient blended IND/SAC cocrystals display a near identical thermal 
profile to that of the unmodified IND/SAC cocrystal, with an absence of any eutectic melt or 
unbound solvents/water. This indicates that the addition of the excipients has had minimal effect 
on the cocrystal yield or purity, demonstrating that excipient blending after the kneading zones has 
not hindered API-coformer interaction or encouraged the formation of amorphous content.  
Further DSC analysis was performed after leaving the samples under accelerated conditions for 
a period of 4 weeks to observe the effect of added excipients on the physical stability of IND/SAC 
cocrystals. The DSC thermogram for 5% and 10% NEU blended cocrystals alongside the 
unmodified IND/SAC cocrystals, before and after stability studies can be seen in Figure 2a. An 
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additional endothermic peak is present at 159.98 °C for the unmodified IND/SAC cocrystals after 
being held under accelerated conditions. This endothermic event can be attributed to the presence 
of recrystallized IND, as the peak position correlates with that of the bulk API. There is a slight 
melting point depression of approximately 1 °C from the usual melting point of IND, but this is a 
well-documented occurrence for recrystallized components in cocrystals. 36 This indicates the 
cocrystal has undergone partial disassociation, likely as a result of dissolution of the SAC coformer 
at high humidities, causing the recrystallization of unbound IND. This type of cocrystal 
disassociation is common at humidities of 75% RH when there is a large solubility difference 
between the API-coformer pair. 14, 37 It is unlikely that hydrate formation had taken place. If the 
cocrystal had dissociated as a result of hydrate formation desorption, evaporation or hydrate 
decomposition in the form of sublimation would have be observed, though the fact that a single, 
sharp endotherm remains in all excipient blended samples indicates no hydrate molecule is present 
in the cocrystal blends. The presence of bound or unbound water molecules on in the cocrystal 
lattice would cause other endothermic events to show in the thermal profile or a significant melting 
point depression, neither of which is present in the excipient blended samples, indicating the 
system is stable. 38 In contrast, both the 5% and 10% excipient blended samples show no such 
endotherm, demonstrating phase stability until the melting point of the cocrystal. This suggests 
that the NEU matrix has hindered any reaction between the SAC coformer and water molecules 
under the increased humidity conditions, thus preventing dissolution of the conformer and 
improving the physical stability of the cocrystal.  
Equivalent data were observed for IND/SAC cocrystals blended with either HPMC or PEG 
6000. As illustrated in Figure 2b, it can be observed that the HPMC blended cocrystals displayed 
excellent stability up until the melting point for both the 5% and 10 % loaded samples after stability 
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testing, indicating that the HPMC matrix has sufficiently protecting the SAC coformer from 
dissolving and maintaining cocrystal integrity. A small, endotherm can be seen in HPMC blended 
IND/SAC cocrystals samples at 242 °C, after the cocrystal melting point. This is likely to be caused 
by the degradation of HPMC left in the pan. Like many other polysaccharides, HPMC will start to 
degrade rather than exhibit melting behaviour and HPMC has been known to undergo physical 
degradation between 225-265°C. 39 This is not an issue for the analysis of the thermal profiles, as 
it occurs after cocrystal melting. Somewhat surprisingly, the IND/SAC cocrystals blended with 
PEG 6000 also displays excellent thermal stability in contrast to the unmodified cocrystal sample. 
As the cocrystals were extruded above PEG 6000s melting point, it was though that interactions 
between cocrystal and excipient were possible. However, the DSC thermogram (Figure 2c) 
displays only one observable event, which correlates to the cocrystal melt, indicating that no 
further interaction between the PEG and bulk excipients has taken place. This is perhaps due to 
the fact that the excipients were added into the extruder in the conveying zones after complete 
cocrystallization had already occurred, preventing competition between the coformer and excipient 
to bind with the IND. That PEG 6000 quickly solidified after discharge from the extruder would 
have given limited time for interaction to occur, which may be another factor contributing to the 
excipients success.    
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Figure 2a: DSC thermal profiles for: unmodified IND/SAC cocrystal, 5% NEU blended cocrystal, 
10% NEU blended cocrystal (blue), unmodified cocrystal after stability testing , 5% NEU cocrystal 




Figure 2b: DSC thermal profiles for: unmodified IND/SAC cocrystal, 5% HPMC blended 
cocrystal, 10% HPMC blended cocrystal, unmodified IND/SAC cocrystal after stability testing, 
5% HPMC cocrystal after stability testing, 10% HPMC cocrystal after stability testing.  
 
 
Figure 2c: DSC thermal profiles for: unmodified IND/SAC cocrystal (black), 5% PEG blended 
cocrystal (red), 10% PEG blended cocrystal (blue), unmodified IND/SAC cocrystal after stability 
testing (Teal), 5% PEG cocrystal after stability testing (Green), 10% PEG cocrystal after stability 
testing (violet).  
 
X-ray Analysis 
The synthesis and quality of the IND/SAC cocrystals were further evaluated through XRPD to 
identify the diffraction patterns of the bulk materials, physical mixture, unmodified IND/SAC 
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cocrystals and excipient blended IND/SAC cocrystals. The analysis of bulk IND showed 
characteristic intensity peaks at 10.25, 11.67, 16.77, 17.02, 19.68, 21.87, 23.99, 26.61° 2θ, while 
Bulk SAC displayed intensity peaks at 9.56, 15.91, 16.02, 17.23, 19.13, 25.14° 2θ (available in 
supporting information Figure S6). The diffractogram for the unmodified IND/SAC cocrystals 
were compared to previously reported structural data published in the CSD (REFCODE: 
UFERED). 27 Our cocrystals were found to be identical to the CSD standard displaying 
characteristic intensity peaks at 5.43, 10.89, 14.42, 21.22, 25.45, and 27.07° 2θ, with the absence 
of any peaks for the unreacted bulk components, indicating a high quality cocrystal (Figure 3).  
However, as can be seen in Figure 4 after four weeks under accelerated conditions (40 ± 1 ºC 
and 75 ± 1.5% RH) the IND/SAC cocrystal displayed newly formed peaks which did not match 
with that of the pure cocrystal. The newly formed peaks at 10.21, 11.67, 21.87° 2θ correlate to 
peaks of IND, indicating the presence of recrystallized bulk IND. 27 This further reinforces the 
idea that the cocrystal has begun to disassociate due to coformer dissolution, leaving excess IND 
in the sample.  
The diffractograms for all excipient blended IND/SAC cocrystals, after being held for stability 
testing for four weeks can be seen in Figure 4 alongside that of the unmodified IND/SAC cocrystal 
before and after stability testing and bulk IND. As can be observed, all excipient blended cocrystals 
display identical structural data to that the pure cocrystal, indicating the extrusion process was a 
success and that the excipients have not interacted with the cocrystal. The absence of any peak for 
bulk IND suggests the excipient matrices have sufficiently protected the cocrystals from 
disassociation under elevated temperatures and humidity.    
To further verify the percentage of the batch which successfully underwent cocrystallization 
Rietveld refinements were carried out for the pure and excipient blended cocrystals before and 
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after stability testing. All samples were fitted to previously published structures for IND, SAC and 
IND/SAC cocrystal, obtained from the CSD. It is generally agreed that if the weighted profile R-
factor (Rwp) is within 3x the expected R factor (Rexp), the fitting can be considered accurate. 
40 In 
this experiment, each Rietveld fitting is within this limit, with no fitting receiving a goodness of 
fit (GoF) above 3, so these results can be considered of excellent quality. It was found that both 
pure and excipient blended, IND/SAC cocrystals have a 100% match with the CSD reference 
structure. This supports the findings from the DSC and diffraction peak analysis and supports the 
hypothesis that feeding the added excipients into the extruder after cocrystallization has occurred 
restricts any possible interaction the excipient may have with the API-coformer pair, leaving the 
cocrystals chemical properties unaffected.  
After being held under accelerated conditions for just 4 weeks, it was found that only 95.4% of 
the unmodified IND/SAC cocrystal was successfully fitted to the CSD reference structure. The 
excess 4.6% of the cocrystal was found to fit to the reference structure for pure IND, confirming 
that the cocrystal has partially dissociated leaving an amount of recrystallized IND. Except in one 
instance; all excipient blended cocrystals have maintained their crystallinity indicating that the 
excipient matrix has improved the physical stability for the IND/SAC cocrystal.   
However, for the cocrystal blended with 10% PEG 6000 the purity of the sample has decreased, 
as the fitting has dropped to 96.33%. The unmatched peaks were found to fit to that of SAC, 
indicating that disassociation had taken place, but leaving excess SAC. This was not seen for the 
5% sample, suggesting the increase in PEG 6000 concentration may have led to a reaction with 
the cocrystal, causing chemical instability. This could be due to the fact that the melting point of 
PEG 6000 (60-64 °C), meaning it is far less thermally stable than the NEU and HPMC. Though 
PEG 6000 is generally regarded as stable in the crystalline form, it has been known to degrade at 
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higher temperatures, facilitating its decomposition. 41 It is plausible that, although the cocrystals 
were held at conditions lower than the melting point, the PEG 6000 started to soften under 
accelerated conditions, causing it to interact with the cocrystal constituents. Recent studies have 
shown that PEG has been known to react with IND in the molten state. Duong et al. (2015) 
demonstrated that each oxygen of the PEG molecule can form hydrogen bonds with two IND 
molecules. 42 This is supported by a study from Chamsai et al. (2012) who found that interactions 
occurred between IND and the similar PEG 4000 under elevated conditions would lead to the 
formation of amorphous IND. 43 This would explain why peaks for SAC were found as the 
formation of amorphous indomethacin would have left traces of unreacted SAC. The fact this was 
not seen in the 5% loaded IND/SAC cocrystals can be attributed to the lesser concentration added 
in the extrusion process, however, it is reasonable to believe that if left for longer, interactions 
between the molten PEG 6000 and IND is possible. Even though the excipient was added after the 
cocrystallization had taken place, the fact it is not thermally stable at higher temperatures and can 
form hydrogen bonds with IND means it has the potential to affect cocrystal purity.  
The chemical instability witnessed with IND/SAC/PEG6000 cocrystals may be due to the 
PEG6000 being soluble with one of the bulk components. Phaechamud et al. (2010), noted 
solubilization of IND when using a 7:3 PEG4000:PEG400 mixture as an inert drug carrier and El-
Badry and colleagues (2009), found that pure PEG 4000 also had a solubilizing effect when 
interacting with IND. 44, 45 Given these findings it is reasonable for one to assume that when left 
for a period of time, the IND began to solubilize within the PEG 6000 matrix causing the chemical 
instability noted in the XRPD analysis, which in turn led to an amount of recrystallized SAC being 
found in the sample after the 4-week period (All data for rietveld fittings displayed in supporting 




Figure 3. X-Ray diffractogram showing 5% NEU blended, 10% NEU blended, 5% HPMC 
blended, 10% HPMC blended, 5% PEG 6000 blended, 10% PEG 6000 blended and unmodified 
IND/SAC cocrystal after extrusion. 
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Figure 4. X-Ray diffractogram showing 5% NEU blended, 10% NEU blended, 5% HPMC 
blended, 10% HPMC blended, 5% PEG 6000 blended, 10% PEG 6000 blended and unmodified 
IND/SAC cocrystal after being held at accelerated conditions for 4 weeks.  
 
Particle size and morphology  
SEM analysis was employed to investigate the surface morphology of the bulk IND, physical 
mixtures and pure and excipient blended IND/SAC cocrystals. The micrograph of the bulk IND 
and unmodified IND/SAC cocrystals (Figures 5 and 6) show the bulk IND to be in the form of 
long irregularly shaped crystals, while the extruded IND/SAC cocrystals are shown to be equant 
shaped and in the form of agglomerates. However, a marked morphological difference can be seen 
between the unmodified IND/SAC cocrystal and those blended with NEU or HPMC excipients. 
While the unmodified IND/SAC cocrystals are in the form of freely moveable agglomerates, a 
dense matrix can be seen to have formed around the NEU and HPLC blended cocrystals. The 
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excipient can be seen to work as a coating, forming a continuous layer around the cocrystals and 
causing them to amalgamate. The characteristic matrix is not present in the structure of the PEG 
6000 blended cocrystals (Figures 5 and 6). This can be attributed to the fact that the PEG 6000 is 
crystalline, while NEU and HPMC are amorphous in structure. 46 This could potentially explain 
why reduced crystallinity was observed in the PEG 6000 blended cocrystals after stability testing. 
In a similar study, where solid dispersions have been processed alongside polymers, it has been 
noted that the continuous layer can prevent the uptake of water molecules, thus dissuading 
hydrogen bonding. 31, 47 As both NEU and HPMC have excellent thermal stability there is little 
chance of this matrix breaking down under accelerated conditions, explaining why cocrystals 
blended with either excipients have showed excellent crystallinity after stability testing. This also 
supports XRPD data, as to why the 10% PEG samples dissociated. The crystalline structure of 
PEG does not allow for the formation of such a layer, meaning moisture uptake and interaction 
with the API is more likely. 
In the cases of the NEU and HPMC loaded cocrystals, the samples blended with 10% of 
excipients seem to exhibit a denser/more viscous matrix. This is confirmed through particle size 
analysis (Figures 7 and 8), where a greater percentage of 10% loaded cocrystals are greater than 
250μm. It should be noted that PEG 6000 blended samples have a far broader particle size 
distribution than the other samples. This may be due to the fact that the NEU and HPMC particles 
have amalgamated into a more organized matrix and that PEG 6000 has a greater particle size than 
the other excipients.  
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Figure 5. SEM images showing unmodified IND/SAC cocrystal (Top left), 5% NEU blended 




Figure 6. SEM images showing bulk IND (Top left), 10% NEU blended (Top right), 10% HPMC 
blended (Bottom left) and 10% PEG 6000 Blended (Bottom right) IND/SAC cocrystals. 
 
Figure 7. Particle size distributions for bulk IND, unmodified IND/SAC cocrystal and 5% loaded 
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Figure 8. Particle size distributions for bulk IND, unmodified IND/SAC cocrystal and 10% loaded 
excipient blended cocrystals. 
Dissolution studies 
As can be seen in Table 1, the unmodified cocrystal showed a moderate level of dissolution in 
the system displaying an IDR of 0.0562mg/min/cm2. Importantly, the pure co-crystal also showed 
a low deviation over the n=3 experiments of 4.75%. The excipient coated cocrystals show similar 
dissolution rates to the unmodified IND/SAC cocrystal despite the additives, as shown in the 
dissolution profile comparison graph (Figure 9.). It can be noted from that the 10% HPMC 
cocrystal, and to a lesser degree the 5% loaded cocrystal, has a much higher IDR value than the 
other excipients, indicating faster dissolution. From the images in Table 3 however, the 10% 
HPMC is showing the formation of a gel in the SDI. Typically, there will be a yellow or light blue 
runoff observed, if the sample was rapidly dissolving, but instead we can observe a swelling around 
a clear focal point (green dot within the surface). This confirms that the higher than expected result 
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Gel was also seen in the flow cell post-dissolution. The formation of the gel leads to an inflated 
IDR as the gel traps the drug which then forms through the IDR zone. Hence, the inflated value of 
0.1478mg/min/cm2 and the higher dissolution profile causing the high. The unpredictable gelling 
behaviour caused large variances in the 3 trials, causing the high standard deviation. The 5% 
HPMC coated cocrystals also displayed some gelling behaviour, however this occurred later in the 
dissolution than with the 10% coated crystals. This behaviour from HPMC samples has been noted 
before in SDI work and has been attributed to the higher viscosity of the polymer. 48 This can be 
attributed to the lower concentration of HPMC present in the sample. Interestingly, the excipient 
coatings didn’t appear to interfere with the dissolution of the co-crystal. This is likely a result of 
there being a low concentration of excipients in the mix, that each chosen excipient has excellent 
water solubility, and that as the excipient is only added to the extrusion process after the last 
kneading zone, the excipients are not interspersed throughout the crystal lattice and instead acts as 
- a protective matrix to the cocrystal. As the selected polymers are water soluble they do not 
negatively affect the dissolution of the cocrystal.  
The in-vitro dissolution rate of the cocrystals co-processed with excipients was assessed, to 
ensure they were not hindering IND release. Here, USP-2 apparatus was utilized to evaluate the 
IND release rates of all excipient blended cocrystals. The excipient blended cocrystal samples were 
dissolved in a buffer solution alongside bulk IND and analysed the concentrations of each to find 
how easily the substance dissolves. IND is a BCS class II drug, meaning it has poor solubility as 
can be seen from (Figure 10.), where only 49% of IND was dissolved in the medium after 2 hours. 
Cocrystallization of indomethacin has been reported to greatly enhances its dissolution rate, so it 
was no surprise that over 92.1% of IND dissolved after 2 hours in the cocrystal samples. 49 The 
dissolution rate of the excipient blended samples closely matches that of the unmodified IND/SAC 
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samples, with only the cocrystals blended with HPMC falling slightly below. The 10% HPMC 
loaded sample released 86.9% after a 2-hour period, which is possibly the result of in-situ gelling 
as was seen in the SDI UV images. Gelling behaviour can slow drug dissolution as the gel will 
form on the sample surface and hinder penetration by the dissolution medium. The 5 % HPMC 
loaded samples dissolution profile closely followed that of the unmodified IND/SAC cocrystals, 
which can be attributed to the lower concentrations. Pajander et al. (2012) found through UV SDI 
imaging that the higher viscosity grade, more rapidly the HPMC will swell, which leads to a thicker 
gel layer, which is more resistant toward the shear forces induced by the flow of the dissolution 
medium. 50 Thus, the dissolution on HPMC blended IND/SAC cocrystals could potentially be 
quickened by using a lower viscosity HPMC. All other samples maintained a good dissolution 
rate, showing that the excipient matrix around the cocrystals will readily dissolve, thus not 













Table 1. Table showing the average intrinsic dissolution rate, standard deviations and UV images 







10% PEG 6000 0.0624 0.0131 21.02
10%  HPMC
10% Neusillin 0.0495





20 minutes Avg. IDR (mg/min/cm2)Batch 1 minute 10 minutes
0.0232 32.85
4.75
5% Neusillin 0.0569 0.0112 19.62





Figure 9. Intrinsic dissolution profiles of the pure and all excipient blended IND/SAC cocrystals. 
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In conclusion, it has been successfully shown that co-processing an API/coformer blend in 
combination with a specific excipient can enhance the physicochemical stability of the resulting 
cocrystal. This study has demonstrated that blending the cocrystal with an NEU or HPMC allows 
the formation of a dense matrix, of which the cocrystal particles are embedded. It can be suggested 
that amorphous excipients are a superior option to crystalline excipients, which did not display the 
same protective matrix seen with the NEU and HPMC blended cocrystals. Furthermore, NEU and 
HPMC possess superior thermal stability than PEG 6000 and are not soluble with either cocrystal 
component, limiting interaction and preventing premature dissociation of the cocrystal. Excipients 
should be inert, non- miscible, have good thermal stability and a low viscosity. This study has 
demonstrated a successful mechanism for co-processing added excipients alongside the cocrystal 
by feeding them into the extruder conveying zones after cocrystallization has taken place, allowing 
for the cocrystal particles to become immersed in the liquefied excipient, before becoming 












Images of extruder and Feeder set-up; Screw configuration, Table of process optimization trials, 
DSC thermograms of bulk IND, SCH, and their physical mixture; XRPD diffractograms of IND, 
SCH, their physical mixtures and the physical mixtures of bulk constituents with the added 
excipients in 5% and 10% loadings; Table of rietveld fitting information’s for unmodified and 
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Physical and chemical stability of indomethacin-saccharin (IND-SAC) cocrystals synthesised via 
hot-melt extrusion (HME) was enhanced through co – processing with inert excipients at the final 
kneading zone. Characterization revealed the added excipients did not interact with the cocrystals 
and instead embedder them in a vicious, protective matrix. Cocrystals co-processed alongside 
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